Gilead SciencesGILDEarnings & Financial Report
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
GILD Q4 FY2025 Key Financial Metrics
Revenue
$7.9B
Gross Profit
$6.3B
Operating Profit
$2.0B
Net Profit
$2.2B
Gross Margin
79.5%
Operating Margin
25.0%
Net Margin
27.5%
YoY Growth
4.7%
EPS
$1.75
Gilead Sciences Q4 FY2025 Financial Summary
Gilead Sciences reported revenue of $7.9B (up 4.7% YoY) for Q4 FY2025, with a net profit of $2.2B (up 22.4% YoY) (27.5% margin). Cost of goods sold was $1.6B, operating expenses totaled $4.3B.
Key Financial Metrics
| Total Revenue | $7.9B |
|---|---|
| Net Profit | $2.2B |
| Gross Margin | 79.5% |
| Operating Margin | 25.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Gilead Sciences Q4 FY2025 revenue of $7.9B breaks down across 12 segments, led by Other at $3.4B (43.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $3.4B | 43.4% |
| HIV Products Biktarvy | $3.3B | 41.1% |
| HIV Products Odefsey | $239.0M | 3.0% |
| Liver Disease Products Other Liver Disease | $170.0M | 2.1% |
| HIV Products Other HIV | $155.0M | 2.0% |
| Other Products Yescarta | $150.0M | 1.9% |
| Liver Disease Products Vemlidy | $149.0M | 1.9% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 1.8% |
| HIV Products Symtuza Revenue Share | $98.0M | 1.2% |
| Veklury | $80.0M | 1.0% |
| Cell Therapy Products Tecartus | $32.0M | 0.4% |
| Royalty Contract And Other | $22.0M | 0.3% |
Gilead Sciences Revenue by Segment — Quarterly Trend
Gilead Sciences revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and HIV Products Biktarvy) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $3.4B | — | $3.4B | $2.7B |
| HIV Products Biktarvy | $3.3B | $2.9B | $2.8B | $2.5B |
| HIV Products Odefsey | $239.0M | $206.0M | — | $215.0M |
| Liver Disease Products Other Liver Disease | $170.0M | $132.0M | — | $68.0M |
| HIV Products Other HIV | $155.0M | $82.0M | $65.0M | $50.0M |
Gilead Sciences Annual Revenue by Year
Gilead Sciences annual revenue history includes year-by-year totals (for example, 2025 revenue was $29.4B).
Gilead Sciences Quarterly Revenue & Net Profit History
Gilead Sciences results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $7.9B | +4.7% | $2.2B | 27.5% |
| Q3 FY2025 | $7.8B | +3.0% | $3.1B | 39.3% |
| Q2 FY2025 | $7.1B | +1.8% | $2.0B | 27.7% |
| Q1 FY2025 | $6.7B | -0.3% | $1.3B | 19.7% |
| Q4 FY2024 | $7.6B | +6.4% | $1.8B | 23.6% |
| Q3 FY2024 | $7.5B | +7.0% | $1.3B | 16.6% |
| Q2 FY2024 | $7.0B | +5.4% | $1.6B | 23.2% |
| Q1 FY2024 | $6.7B | +5.3% | $-4.2B | -62.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.69B | $6.95B | $7.54B | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B |
| YoY Growth | 5.3% | 5.4% | 7.0% | 6.4% | -0.3% | 1.8% | 3.0% | 4.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $56.29B | $53.58B | $54.52B | $58.99B | $56.43B | $55.72B | $58.53B | $59.02B |
| Liabilities | $38.75B | $35.30B | $36.05B | $39.66B | $37.27B | $36.05B | $36.99B | $36.32B |
| Equity | $17.54B | $18.28B | $18.48B | $19.33B | $19.16B | $19.67B | $21.54B | $22.70B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.22B | $1.32B | $4.31B | $2.98B | $1.76B | $827.0M | $4.11B | $3.33B |